FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Leukocyte topics
Leukocytes
Immunogenic
Stem Cells
Immune System
Animal Model
Human Leukocyte Antigen
Transgenic
Stimulator
Macrophage
Thromboxane
Attenuated
Fibronectin
Chronic Obstructive Pulmonary Disease
Antagonist
Vaccination

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukocyte patents



      
           
This page is updated frequently with new Leukocyte-related patent applications. Subscribe to the Leukocyte RSS feed to automatically get the update: related Leukocyte RSS feeds. RSS updates for this page: Leukocyte RSS RSS


Canadian Blood Services

Acellular pro-tolerogenic compositions and process for making same

Date/App# patent app List of recent Leukocyte-related patents
06/25/15
20150174203
 Compositions and methods for modulating pro-inflammatory immune response patent thumbnailnew patent Compositions and methods for modulating pro-inflammatory immune response
Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (lilr) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a lilr protein..
The Board Of Regents, The University Of Texas System
06/25/15
20150174168
 Acellular pro-tolerogenic compositions and process for making same patent thumbnailnew patent Acellular pro-tolerogenic compositions and process for making same
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services
06/18/15
20150168426
 Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension patent thumbnailMethods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (cd31+/41−), pan-leukocyte (cd11a+), lymphocyte (cd4+), erythrocyte (cd235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.. .
Assistance Publique - Hopitaux De Paris
06/18/15
20150165102
 Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device patent thumbnailIntegrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device
A blood filter device comprising: a housing comprising an outer wall and a first inlet, a first outlet and a second outlet; a membrane which is capable of separating plasma from the blood, wherein the membrane forms an inner chamber; a leukocyte and oxygen and/or carbon dioxide depletion media disposed wherein the inner chamber, the leukocyte and oxygen and/or carbon dioxide depletion media is capable of depleting leukocytes and oxygen and/or carbon dioxide from the blood; an outer chamber disposed between the outer wall and the membrane, wherein the plasma which permeates through the membrane enters the outer chamber and exits the filter device via the first outlet; whereby the blood which has been depleted of oxygen and/or carbon dioxide, leukocytes and plasma exists and filter device via the second outlet.. .
New Health Sciences, Inc.
06/18/15
20150164948
 Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases patent thumbnailAcellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services
05/14/15
20150132739
 Multilayered blood product patent thumbnailMultilayered blood product
A blood product (10), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes.
05/14/15
20150132738
 Method for identification of non-hematogeneous karocytes enriched from body fluid of humans or animals patent thumbnailMethod for identification of non-hematogeneous karocytes enriched from body fluid of humans or animals
Disclosed is a method for identification of non-hematogenous karyocytes enriched from body fluid of humans or animals, wherein immunofluorescent staining of antibodies against human leukocytes and fluorescence in situ hybridizationof chromosome are carried out synchronously to distinguish hematogenous karyocytes and the interference produced by the hematogenous karyocytes during the judgement on tumour cells is removed effectively, thus achieving efficient and rapid enrichment and extraction from human body fluid of non-hematogenous rare cancer cells originating from the epithelium or not originating from the epithelium and effective identification. The method provided by the present invention does not need to lyse and break red blood cell and without influencing the targeted cell in human body fluid, thus the original cell shape is maintained very well, which is convenient for the subsequent identification and judgement of cells..
05/14/15
20150132217
 Disease therapy by inducing immune response to trop-2 expressing cells patent thumbnailDisease therapy by inducing immune response to trop-2 expressing cells
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
04/30/15
20150118728
 Apparatus and  separating a biological entity from a sample volume patent thumbnailApparatus and separating a biological entity from a sample volume
According to embodiments of the present invention, an apparatus for separating a biological entity from a sample volume is provided. The apparatus includes an input chamber including an inlet configured to receive the volume sample, and an outlet, at least one magnetic element adjacent a portion of the input chamber, the magnetic element configured to provide a magnetic field in a vicinity of the portion of the input chamber to trap at least some leukocytes from the sample volume, and a filter in fluid communication with the outlet, the filter configured to separate the biological entity.
Agency For Science, Technology And Research
04/30/15
20150118109
 Component preparation system patent thumbnailComponent preparation system
Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system..
New York Blood Center, Inc.
04/23/15
20150111947

Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage


Provided herein are methods of decreasing leukocyte extravasation from a lymph or blood vessel into a tissue in a mammal, methods of decreasing fluid leakage from a lymph or blood vessel in a mammal in need thereof, methods of decreasing formation of atherosclerotic plaques in a mammal in need thereof, and methods of treating atherosclerosis in a mammal that include administering to the mammal an oligonucleotide that decreases mitogen-activated protein kinase kinase kinase kinase 4 (map4k4) mrna expression in an endothelial cell. Also provided are methods of identifying a candidate agent useful for decreasing leukocyte extravasation or decreasing fluid leakage from a lymph or blood vessel in a mammal, and compositions containing an oligonucleotide that decreases map4k4 mrna expression in an endothelial cell and additional therapeutic agents..
University Of Massachusetts
04/23/15
20150111783

Compositions and methods for the detection of antibodies to native human leukocyte antigen


Provided herein are compositions comprising native and denatured human leukocyte antigens (hla) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native hlas..
One Lambda, Inc.
04/16/15
20150104467

Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease


Methods for treating and reducing the progression of neurodegenerative diseases, including, without limitation alzheimer's disease, are provided. The methods of the invention reduce or deplete neutrophil/myeloid cells in the region of the brain by blocking neutrophil/myeloid cell adhesion and interaction with the vascular endothelium, by blocking infiltration of neutrophil/myeloid cells into the brain, by reducing motility of neutrophil/myeloid cells in the parenchyma, by blocking aβ-induced activation and adhesion of neutrophil/myeloid cells, and/or by blocking aβ-induced integrin activation, degranulation and/or ros release in neutrophil/myeloid cells..
Leuvas Therapeutics
04/09/15
20150096938

Removal of immunoglobulins and leukocytes from biological fluids


Devices, systems, and methods for depleting fluids of immunoglobulins and leukocytes are disclosed.. .
Pall Corporation
03/26/15
20150087663

Substituted aminopyrimidine compounds and methods of use


The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not limited to leukemias and solid tumors, in mammals, especially humans..
Calitor Sciences, Llc
03/26/15
20150087658

Substituted aminopyrimidine compounds and methods of use


The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans..
Sunshine Lake Pharma Co., Ltd.
03/26/15
20150087005

Phosphorothioate oligonucleotide-labeling of white blood cells


The present invention provides labeling and capture reagents that comprise phosphorothioate oligonucleotides odn). The ps-odn bind to all white blood cells (leukocytes) in an indiscriminative fashion and enable the labeling, capture, or concentration of leukocytes in a manner that preserves the antigenic integrity of the cells.
Becton, Dickinson And Company
03/05/15
20150064177

Therapeutic uses of humanized antibodies against alpha-4 integrin


The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, aids dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury..
Biogen Idec Ma Inc.
03/05/15
20150064153

High efficiency microfluidic purification of stem cells to improve transplants


Described herein is a novel, highly efficient system to remove erythrocytes and purify leukocytes would raise the quality of ucb and other transplant grafts, thereby significantly improving patient outcomes.. .
University Of Maryland, Baltimore
02/26/15
20150056678

Disease therapy using dying or dead cells


A method of treating a disease characterized by a pathological immune response in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of a cell preparation which comprises dying or dead leukocytes, the dying or dead leukocytes being capable of suppressing the pathological immune response, thereby treating the disease in the subject..
Enlivex Therapeutics Ltd.
02/26/15
20150056225

Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof


The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a human leukocyte antigen (hla) class ii-related gene, which results in deficiency in mhc class ii expression and function. This invention also provides isolated cells further comprising a genetically engineered disruption in a beta-2 microglobulin (b2m) gene, which results in hla class i/class ii deficiency.
University Of Washington Through Its Center For Commercialization
02/19/15
20150051259

Pro-inflammatory mediators in diagnosis and treatment of pulmonary disease


Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease. Various pro-inflammatory mediators are elevated in a model of copd that can be used predict the presence of copd and/or subtypes of copd in human patients.
National Jewish Health
02/19/15
20150051156

Method of treating leukemia using rice prolamin


The present invention relates to a method of treating leukemia using rice prolamin, comprising administering a daily dose of isolated prolamin to a patient suffering from leukemia for a period of time from 5 days to 10 days. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (pbmc) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia cells.
Mackay Memorial Hospital
02/12/15
20150044141

Synthesis and application of novel imaging agents conjugated to dpa 713 analogs for imaging inflammation


The present invention provides analog compounds of dpa-713 which specifically bind the translocator protein (tspo), which is upregulated in activated leukocytes, some malignant tumors and tissues involved in steroid biogenesis. These compounds are linked via a linking moiety to a variety of imaging agents, including, for example, near infra-red dyes.
The Johns Hopkins University
02/05/15
20150037789

Systemic genotoxicity as blood marker for allergic inflammation


The invention provides a method for detection of allergic inflammation in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammation.
The Regents Of The University Of California
02/05/15
20150037346

Prediction of responsiveness to treatment with immunomodulatory therapeutics and monitoring abscopal effects during such treatment


Efficacy of a therapeutic to enhance antitumor immunity in a patient is predicted, where the therapeutic is one that targets an immunomodulatory leukocyte membrane protein (ilmp) to enhance immune activity. Peripheral blood sample from the patient is tested for levels of monocytes having specific cell surface markers (cd14+, hla-drlow) prior to treatment.
Sloan-kettering Institute For Cancer Research
01/29/15
20150030500

Irradiation inactivating pathogens and/or leukocytes in a biological fluid and process


The invention relates to an irradiation apparatus for inactivating pathogens and/or leukocytes in a biological fluid such as a platelet suspension and/or plasma comprising: a casing (2), a support member (3) for carrying at least one irradiation bag (19) containing the biological fluid, a light source (4) comprising two banks of light (5, 6) disposed above and below the support member (3), and an agitating system (25) for moving the support member (3), the light source generating uvc light of suitable intensity to inactivate pathogens and/or leukocytes and the agitation system moving the support member in an orbital path with predetermined amplitude and rotational frequency suitable to expose the whole biological fluid to uvc.. .
Maco Pharma S.a.
01/22/15
20150023994

Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof


Provided are the use of the recombinant ganoderma lucidum immunomodulatory protein (rlz-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rlz-8 protein, wherein the rlz-8 protein is expressed from pichia yeast.. .
01/15/15
20150017643

Method of molecular typing


The invention relates to the identification of genetic traits in an individual. More specifically, the invention relates to identifying human leukocyte antigen (hla) alleles and haplotypes in a potential donor sample.
Nhs Blood & Transplant
01/08/15
20150010923

Method for labeling intracellular and extracellular targets of leukocytes


The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.. .
Beckman Coulter, Inc.
01/01/15
20150006086

Personal compatibility using hla


Processing personal compatibility matches includes a computer system receiving input of a first allele group determined to be present in a first person and a second allele group determined to be present in a second person. The first allele group and the second allele group are members of a set of allele groups for a human leukocyte antigen (hla) gene.
Instant Chemistry Inc.
01/01/15
20150005179

Hla primers for personal compatibility


Processing personal compatibility matches includes a computer system receiving input of a first allele group determined to be present in a first person and a second allele group determined to be present in a second person. The first allele group and the second allele group are members of a set of allele groups for a human leukocyte antigen (hla) gene.
Instant Chemistry Inc.
12/25/14
20140378479

Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta


Compounds that inhibit pi3kδ activity, including compounds that selectively inhibit pi3kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (pi3kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which pi3kδ plays a role in leukocyte function, using the compounds also are disclosed..
Icos Corporation
12/25/14
20140377777

Methods and compositions for diagnosis and prognosis of renal injury and renal failure


The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of insulin-like growth factor-binding protein 7, beta-2-glycoprotein 1, metalloproteinase inhibitor 2, alpha-1 antitrypsin, leukocyte elastase, serum amyloid p component, c-x-c motif chemokine 6, immunoglobulin a, immunoglobulin g subclass i, c-c motif chemokine 24, neutrophil collagenase, cathepsin d, c-x-c motif chemokine 13, involucrin, interleukin-6 receptor subunit beta, hepatocyte growth factor, cxcl-1, -2, -3, immunoglobulin g subclass ii, metalloproteinase inhibitor 4, c-c motif chemokine 18, matrilysin, c-x-c motif chemokine 11, and antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient..
Astute Medical, Inc.
12/25/14
20140377742

Microfluidic device


Described herein are particular embodiments relating to a microfluidic device that may be utilized for cell sensing, counting, and/or sorting. Particular aspects relate to a microfabricated device that is capable of differentiating single cell types from dense cell populations.
California Institute Of Technology
12/04/14
20140357840

Method for obtaining a dialyzable leukocyte extract


The present invention relates to a method for producing a transfer factor. The method comprises the following steps: freezing and thawing of peripheral-blood leukocytes, dialysis, tangential ultrafiltration, identification and quantification using high-resolution, molecular-exclusion liquid chromatography, and in vitro biological validation.
11/20/14
20140342375

Microfluidic processing of leukocytes for molecular diagnostic testing


Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas..
11/13/14
20140335149

Wound-healing promoting material


The object of the present invention is to provide a means for utilizing cells that have effects on wound healing as wound-healing promoting materials by efficiently concentrating such cells within a short period of time. The present invention provides a wound-healing promoting material which comprises a sheet-like porous body having on its surface at least leukocytes and/or platelets, a method for producing the same, a device for producing the same, and a method for treating wound sites using the same..
11/06/14
20140329809

New leukocyte infiltrate markers for rosacea and uses thereof


A process for the characterization of rosacea is disclosed. The process can include identifying for the first time new markers in leukocyte recruitment as well as the therapeutic applications targeting rosacea..
10/23/14
20140315242

Microfluidic chamber assembly for mastitis assay


The present invention relates to a device and method for the detection of mastitis or other disease from a body fluid of a mammal for example from cow's milk. The device and method relates to a wedge microfluidic chamber for using a minimal amount of fluid and being able to use the device to observe leukocytes in a mono-layer for the purpose of disease detection, cell counts or the like..
10/09/14
20140303026

Compounds for modulating integrin cd11b/cd18


The application describes an assay for the identification of small molecule modulators of integrin cd11b/cd18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (aids), myeloperoxidase deficiency, wiskott-aldrich syndrome, chronic granulomatous disease, hyper-igm syndromes, leukocyte adhesion deficiency, chediak-higashi syndrome, and severe combined immunodeficiency..
10/02/14
20140295550

Hla peptide therapy


The invention provides polypeptides derived from a major histocompatibility complex (mhc) class i human leukocyte antigen (hla), such as hla-a2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection..
10/02/14
20140291227

Leukocyte filtration unit with reduced platelet adhesion


A filtration unit to selectively remove leukocytes from fluids containing platelets and systems including a filtration unit are provided. In one embodiment, a filtration unit is provided including an outer casing enclosing a porous element which includes a leukocyte-removal medium with a coating.


Popular terms: [SEARCH]

Leukocyte topics: Leukocytes, Immunogenic, Stem Cells, Immune System, Animal Model, Human Leukocyte Antigen, Transgenic, Stimulator, Macrophage, Thromboxane, Attenuated, Fibronectin, Chronic Obstructive Pulmonary Disease, Antagonist, Vaccination

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukocyte for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukocyte with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.2743

3374

0 - 1 - 72